1. patient has sars-cov-2 infection of severity ≥ 6 on covid-19 who ordinal scale for clinical improvement or for those subjects who have a who ordinal scale for clinical improvement score of 5, nasal intermittent positive pressure ventilation (nippv) or requiring hfno \> 20 l/min with fio2 ≥ 0.5 will be exclusionary. 2. patient is currently receiving extracorporeal membrane oxygenation, nitric oxide therapy, or high-frequency oscillatory ventilation 3. patient is unlikely to survive for \> 24 hours from randomization, in the opinion of the investigator 4. patient has a history of chronic oxygen use or any pre-existing respiratory condition that requires intermittent or continuous ambulatory oxygen prior to hospitalization 5. patient has a history of venous thromboembolism, dvt, or pulmonary embolus 6. has taken other investigational drugs or participated in any clinical study within 30 days or 5 half-lives (if known) of the investigational drug's pk, pd, or biological activity (if known), whichever is longer, prior to the first dose of study drug in this study or is currently participating in another clinical study.

1. patient has sars-cov-2 infection of severity ≥ 6 on covid-19 who ordinal scale for clinical improvement or for those subjects who have a who ordinal scale for clinical improvement score of 5, nasal intermittent positive pressure ventilation (nippv) or requiring hfno \> 20 l/min with fio2 ≥ 0.5 will be exclusionary. 2. patient is currently receiving extracorporeal membrane oxygenation, nitric oxide therapy, or high-frequency oscillatory ventilation 3. patient is unlikely to survive for \> 24 hours from randomization, in the opinion of the investigator 4. patient has a history of chronic oxygen use or any pre-existing respiratory condition that requires intermittent or continuous ambulatory oxygen prior to hospitalization 5. patient has a history of venous thromboembolism, dvt, or pulmonary embolus 6. has taken other investigational drugs or participated in any clinical study within 30 days or 5 half-lives (if known) of the investigational drug's pk, pd, or biological activity (if known), whichever is longer, prior to the first dose of study drug in this study or is currently participating in another clinical study.

patient has sars-cov-2 infection of severity ≥ 6 on covid-19 who ordinal scale for clinical improvement or for those subjects who have a who ordinal scale for clinical improvement score of 5, nasal intermittent positive pressure ventilation (nippv) or requiring hfno > 20 l/min with fio2 ≥ 0.5 will be exclusionary. patient is currently receiving extracorporeal membrane oxygenation, nitric oxide therapy, or high-frequency oscillatory ventilation patient is unlikely to survive for > 24 hours from randomization, in the opinion of the investigator patient has a history of chronic oxygen use or any pre-existing respiratory condition that requires intermittent or continuous ambulatory oxygen prior to hospitalization patient has a history of venous thromboembolism, dvt, or pulmonary embolus has taken other investigational drugs or participated in any clinical study within 30 days or 5 half-lives (if known) of the investigational drug's pk, pd, or biological activity (if known), whichever is longer, prior to the first dose of study drug in this study or is currently participating in another clinical study.

patient has sars-cov-2 infection of severity ≥ 6 on covid-19 who ordinal scale for clinical improvement or for those subjects who have a who ordinal scale for clinical improvement score of 5, nasal intermittent positive pressure ventilation (nippv) or requiring hfno > 20 l/min with fio2 ≥ 0.5 will be exclusionary. patient is currently receiving extracorporeal membrane oxygenation, nitric oxide therapy, or high-frequency oscillatory ventilation patient is unlikely to survive for > 24 hours from randomization, in the opinion of the investigator patient has a history of chronic oxygen use or any pre-existing respiratory condition that requires intermittent or continuous ambulatory oxygen prior to hospitalization patient has a history of venous thromboembolism, dvt, or pulmonary embolus has taken other investigational drugs or participated in any clinical study within 30 days or 5 half-lives (if known) of the investigational drug's pk, pd, or biological activity (if known), whichever is longer, prior to the first dose of study drug in this study or is currently participating in another clinical study.

1. patient has sars-cov-2 infection of severity ≥ 6 on covid-19 who ordinal scale for clinical improvement or for those subjects who have a who ordinal scale for clinical improvement score of 5, nasal intermittent positive pressure ventilation (nippv) or requiring hfno > 20 l/min with fio2 ≥ 0.5 will be exclusionary. 2. patient is currently receiving extracorporeal membrane oxygenation, nitric oxide therapy, or high-frequency oscillatory ventilation 3. patient is unlikely to survive for > 24 hours from randomization, in the opinion of the investigator 4. patient has a history of chronic oxygen use or any pre-existing respiratory condition that requires intermittent or continuous ambulatory oxygen prior to hospitalization 5. patient has a history of venous thromboembolism, dvt, or pulmonary embolus 6. has taken other investigational drugs or participated in any clinical study within 30 days or 5 half-lives (if known) of the investigational drug's pk, pd, or biological activity (if known), whichever is longer, prior to the first dose of study drug in this study or is currently participating in another clinical study.

1. patient has sars-cov-2 infection of severity ≥ 6 on covid-19 who ordinal scale for clinical improvement or for those subjects who have a who ordinal scale for clinical improvement score of 5, nasal intermittent positive pressure ventilation (nippv) or requiring hfno > 20 l/min with fio2 ≥ 0.5 will be exclusionary. 2. patient is currently receiving extracorporeal membrane oxygenation, nitric oxide therapy, or high-frequency oscillatory ventilation 3. patient is unlikely to survive for > 24 hours from randomization, in the opinion of the investigator 4. patient has a history of chronic oxygen use or any pre-existing respiratory condition that requires intermittent or continuous ambulatory oxygen prior to hospitalization 5. patient has a history of venous thromboembolism, dvt, or pulmonary embolus 6. has taken other investigational drugs or participated in any clinical study within 30 days or 5 half-lives (if known) of the investigational drug's pk, pd, or biological activity (if known), whichever is longer, prior to the first dose of study drug in this study or is currently participating in another clinical study.